摘要
目的观察肝硬化患者血清胃蛋白酶原(PG)水平,分析血清PG水平与肝硬化门脉高压胃病(PHG)严重程度相关性。方法选取2015年6月至2018年3月在本院接受治疗的试验组肝硬化患者110例,其中肝炎肝硬化77例,酒精性硬化18例,自身免疫性肝硬化9例,原发性胆汁淤积性肝硬化6例。对照组为健康体检者20名。全部参与对象检查胃黏膜状态诊断PHG,其中肝硬化不合并PHG组59例为试验1组,肝硬化合并轻度PHG 31例为试验2组,肝硬化合并重度PHG 20例为试验3组。检测试验组、对照组及不同类别硬化病例血清中PGⅠ、PGⅡ的含量,进行数据分析比对。结果对照组血清PGⅠ水平(183±62)μg/L均高于试验1组(160±53)μg/L、试验2组(82±34)μg/L、试验3组(85±35)μg/L(P<0.05);试验1组血清PGⅠ水平高于试验2组、试验3组(P<0.05);试验1组PGⅡ水平(17±5)μg/L和对照组血清中PGⅡ(23±6)μg/L水平均高于试验2组(13±4)μg/L、试验3组(12±4)μg/L(P<0.05);对照组血清中PGⅡ水平高于试验2组(P>0.05);试验1组、试验2组、试验3组中PGⅠ、PGⅡ值中位数值递减;不同病因肝硬化患者血清中PG水平比较差异无统计学意义。结论血清PGⅠ和PGⅡ能较好地评估胃黏膜分泌功能,可初步预测肝硬化PHG的形成,依据两者含量水平对不同病程的PHG进行评估和临床治疗。
Objective To observe the serum pepsinogen (PG) level in patients with liver cirrhosis and to analyze the correlation between the serum PG level and severity of cirrhosis portal hypertensive gastropathy(PHG). Methods The experimental group consisted 110 patients with liver cirrhosis treated in our hospital from June 2015 to March 2018, including 77 cases of liver cirrhosis,18 cases of alcoholic liver cirrhosis,9 cases of autoimmune cirrhosis and 6 cases of primary biliary cirrhosis. The control group consisted of 20 healthy subjects. All participants participated in the diagnosis of gastric mucosal PHG. Among them, 59 cases of cirrhosis without PHG were treated as experimental group 1, 31 cases of cirrhosis with mild PHG as experimental group 2, 20 cases of cirrhosis with severe PHG as experimental group 3. The serum levels of PG I and PGⅡ in the experimental group, the control group and different kinds of sclerosis cases were detected. The data were analyzed and compared. Results The serum PG I levels in the control group (183±62)μg/L were higher than those in the experimental group 1 (160±53)μg/L, experimental group 2 (82±34)μg/L, experimental group 3 (85±35)μg/L, respectively (P<0.05);the serum PG I levels in the experimental group 1 were higher than those of the experimental group 2 and experimental group 3, respectively (P<0.05);the serum PGⅡlevels in the experimental group 1 (17±5)μg/L and control group (23±6)μg/L were higher than those of the experimental group 2 (13±4)μg/L, experimental group 3 (12±4)μg/L, respectively (P<0.05);the serum PGⅡ levels in the control group were higher than that of the experimental group 2 (13±4)(P>0.05);the PG I and PGⅡ value in experimental group 1, experimental group 2, experimental group 3 decreased progressively;the serum PG levels in patients with different etiology of liver cirrhosis compared little difference, no statistically significant. Conclusion Serum PG I and PGⅡ can better evaluate the secretion function of gastric mucosa, and can predi
作者
张芙蓉
宋丽
韦兴静
Zhang Furong;Song Li;Wei Xingjing(Department of Gastroenterology, Beijing Yanhua Hospital, Beijing 102500, China)
出处
《山西医药杂志》
CAS
2019年第4期423-425,共3页
Shanxi Medical Journal
关键词
肝硬化
胃蛋白酶原类
门脉高压胃病
Liver cirrhosis
Pepsinogens
Portal hypertensive gastropathy
